Affiliation:
1. Harvard Medical School, Boston, Massachusetts
2. Joslin Diabetes Center, Boston, Massachusetts
3. Children's Hospital Boston, Boston, Massachusetts
Abstract
OBJECTIVE—Sedentary lifestyle and a western diet promote subacute-chronic inflammation, obesity, and subsequently dysglycemia. The aim of the current study was to evaluate the efficacy of the anti-inflammatory drug salsalate to improve glycemia by reducing systemic inflammation in obese adults at risk for the development of type 2 diabetes.
RESEARCH DESIGN AND METHODS—In a double-masked, placebo controlled trial, we evaluated 20 obese nondiabetic adults at baseline and after 1 month of salsalate or placebo.
RESULTS—Compared with placebo, salsalate reduced fasting glucose 13% (P < 0.002), glycemic response after an oral glucose challenge 20% (P < 0.004), and glycated albumin 17% (P < 0.0003). Although insulin levels were unchanged, fasting and oral glucose tolerance test C-peptide levels decreased in the salsalate-treated subjects compared with placebo (P < 0.03), consistent with improved insulin sensitivity and a known effect of salicylates to inhibit insulin clearance. Adiponectin increased 57% after salsalate compared with placebo (P < 0.003). Additionally, within the group of salsalate-treated subjects, circulating levels of C-reactive protein were reduced by 34% (P < 0.05).
CONCLUSIONS—This proof-of-principle study demonstrates that salsalate reduces glycemia and may improve inflammatory cardiovascular risk indexes in overweight individuals. These data support the hypothesis that subacute-chronic inflammation contributes to the pathogenesis of obesity-related dysglycemia and that targeting inflammation may provide a therapeutic route for diabetes prevention.
Publisher
American Diabetes Association
Subject
Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference40 articles.
1. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685–1695, 2005
2. Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance. J Clin Invest 116: 1793–1801, 2006
3. Ebstein W: Zur therapie des diabetes mellitus, insbesondere über die anwendeng der salicylauren natron bei demselben. Berl Klin Wochenschr 13: 337–340, 1876
4. Williamson R: On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J 1: 760–762, 1901
5. Reid J, Macdougall AI, Andrews MM: Aspirin and diabetes mellitus. Br Med J 33: 1071–1074, 1957
Cited by
306 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献